Analyst firms · Morgan Stanley · ASND
Morgan Stanley ASND price target and rating history
Ascendis Pharma A/S (ASND) · Health Care
Morgan Stanley rates Ascendis Pharma A/S (ASND) Overweight with a $250 price target, as of its latest action on Jul 3, 2025. It has published 5 rating actions on ASND since August 2021, including 1 upgrade and 1 downgrade. Across 6 firms with a ASND price target in the last 12 months, the median target is $330.50.
- Current rating
- Overweight
- Price target
- $250
- Median target, all firms
- $330.50
- Actions on ASND
- 5
Morgan Stanley price target on ASND
Every Morgan Stanley rating on ASND
- Jul 3, 2025
- May 5, 2025
- Apr 4, 2023
- Mar 7, 2022
- Aug 26, 2021
How other firms rate ASND
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Raymond James | Outperform | $287 | Sep 15, 2026 |
| H.C. Wainwright | Buy | $345 | Aug 27, 2026 |
| BMO Capital Markets | Outperform | $319 | Aug 19, 2026 |
| Citigroup | Buy | $355 | May 19, 2026 |
| Jefferies | Buy | Mar 16, 2026 | |
| Barclays | Overweight | $342 | Jan 28, 2026 |
| Wolfe Research | Peer Perform | $255 | Nov 18, 2025 |
Questions about Morgan Stanley and ASND
- What is Morgan Stanley's price target for ASND?
- Morgan Stanley's latest stated price target for Ascendis Pharma A/S (ASND) is $250, from its action on Jul 3, 2025.
- What is Morgan Stanley's rating on ASND?
- Morgan Stanley rates ASND Overweight, a bullish rating, as of Jul 3, 2025.
- When did Morgan Stanley last change its view on ASND?
- On Jul 3, 2025, Morgan Stanley resumes coverage at Overweight, price target $250.
- How does Morgan Stanley's ASND target compare with other analysts?
- Across 6 firms with a ASND price target in the last 12 months, the median target is $330.50.
More ASND rating histories
All Morgan Stanley ratingsASND news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.